- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03871075
Intermittent Pneumatic Compression With and Without Exercise to Improve Functioning in Peripheral Artery Disease (INTERCEDE)
Intermittent Pneumatic Compression With and Without Exercise to Improve Functioning in Peripheral Artery Disease: The INTERCEDE TRIAL
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Kathryn Domanchuk, BS
- Phone Number: 312-503-6438
- Email: k-domanchuk@northwestern.edu
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- Recruiting
- University of Chicago
-
Contact:
- Tamar Polonsky, MD
- Phone Number: 773-702-6153
- Email: tpolonsky@bsd.uchicago.edu
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern University
-
Contact:
- Mary McDermott, MD
- Phone Number: 312-503-6419
- Email: mdm608@northwestern.edu
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Recruiting
- Henry Ford Health
-
Contact:
- Jonathan Ehrman, PhD
- Phone Number: 313-972-4089
- Email: jehrman1@hfhs.org
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Recruiting
- University of Minnesota
-
Contact:
- Diane Treat-Jacobson, PhD
- Phone Number: 612-624-7613
- Email: treat001@umn.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
All participants will have PAD. PAD will be defined as follows: first, an ankle-brachial index (ABI) < or = 0.90 at the baseline study visit is an inclusion criterion for PAD. Second, potential participants with an ABI >0.90 who have vascular laboratory evidence of PAD. Vascular laboratory evidence consists of objective evidence of PAD, including toe brachial index (TBI) < or = 0.70, Duplex measure showing 70% stenosis or greater, or ABI values < 0.90. Abnormal waveforms or pulse volume recordings alone from a non-invasive vascular laboratory test will not be sufficient for enrollment. Third, potential participants with an ABI >0.90 who have angiographic evidence of PAD consisting of a stenosis of 70% or greater in a lower extremity artery.
Exclusion Criteria:
- Above- or below-knee amputation.
- Critical limb ischemia or ABI < 0.30 in the setting of ischemic symptoms at rest or physical examination findings consistent with critical limb ischemia. Some potential participants with symptoms or signs of critical limb ischemia may be excluded at the principal investigator's discretion if the ABI is 0.30 or higher.
- Wheelchair-bound.
- Current foot ulcer on bottom of foot.
- Walking is primarily limited by a symptom other than PAD.
- Failure to successfully complete the study run-in.
- Major surgery, revascularization, or orthopedic surgery in the past 3 months or planned in the next 12 months.
- Major medical illness including Parkinson's Disease, lung disease requiring oxygen, cancer requiring treatment in the previous two years, or life-threatening illness with a life expectancy of less than six months. Participants who only use oxygen at night will be potentially eligible. [NOTE: potential participants treated for cancer in the past two years may still qualify if they have had treatment for early stage cancer in the past two years and the prognosis is excellent. Potential participants treated for basal cell or squamous cell skin cancer will not be excluded.]
- Already exercising at a level consistent with exercise intervention. Current or recent participation in exercise rehabilitation (within the past three months).
- Recently diagnosed (within the past three months) with acute lower extremity deep venous thrombosis, pulmonary embolism, or severe heart failure (i.e. New York Heart Association (NYHA) Class III or IV).
- Mini-Mental Status Examination (MMSE) score <23 or dementia.
- Participation in or completion of a clinical trial in the previous three months.
- Non-English speaking.
- Increase in angina in the past month, angina at rest, or abnormal baseline treadmill stress test. Potential participants may become eligible after an abnormal baseline treadmill stress test if they have evidence of an absence of coronary ischemia based on testing (such as a stress test with imaging or a coronary angiogram) from a test performed with their own physician and if they do not have symptoms of unstable angina. The evidence of absent coronary ischemia, based on an imaging stress test or coronary angiogram, must have been performed within the previous year.
- Ongoing infection of the toes, foot, or lower extremity.
- Potential participants who started on cilostazol within the last three months. They may be evaluated for eligibility once three months have passed since beginning cilostazol.
- Significant peripheral edema, defined as 3+ or greater edema severity, as determined by the principal investigator.
- BMI >45 kg/M2
- Significant visual impairment that interferes with walking.
- In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IPC + exercise
Participants will be asked to wear the intermittent pneumatic compression device for up to three hours daily.
They will be helped to engage in home-based walking exercise therapy.
|
Intermittent pneumatic compression is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves.
The cuffs rapidly inflate to a pressure of 120 mm Hg, which is sustained for three seconds, followed by rapid deflation.
Participants will be asked to wear the device for two hours daily.
The device will inflate 180 times/hour.
Other Names:
Participants will be asked to walk for exercise five days/week, working up to 50 minutes of exercise per day.
The intervention includes a) group meetings at the medical center with the coach and other PAD participants; b) regularly scheduled individual telephone check-in by the coach c) weekly remote monitoring by the coach; d) use of the activity monitor to monitor exercise intensity and duration.
|
Experimental: IPC + "no exercise" control
Participants will be asked to wear the intermittent pneumatic compression device for up to three hours daily.
They will be asked to participate in an educational/informational intervention consisting of an attention control intervention
|
Intermittent pneumatic compression is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves.
The cuffs rapidly inflate to a pressure of 120 mm Hg, which is sustained for three seconds, followed by rapid deflation.
Participants will be asked to wear the device for two hours daily.
The device will inflate 180 times/hour.
Other Names:
Participants attend health-education lectures and receive telephone calls at the same frequency as the exercise group.
On-site lectures are delivered by faculty and staff at the medical center.
Telephone calls review health-related handouts from the NIA website that are mailed in advance of the telephone call.
Content does not include exercise information.
|
Active Comparator: sham control + exercise
Participants will be asked to wear a sham intermittent pneumatic compression device for up to three hours daily.
The sham device inflates at the same frequency, but to a much lower systolic pressure, compared to the therapeutic pneumatic compression device.
Participants in this group will be helped to engage in home-based walking exercise therapy.
|
Participants will be asked to walk for exercise five days/week, working up to 50 minutes of exercise per day.
The intervention includes a) group meetings at the medical center with the coach and other PAD participants; b) regularly scheduled individual telephone check-in by the coach c) weekly remote monitoring by the coach; d) use of the activity monitor to monitor exercise intensity and duration.
The sham control device is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves.
The cuffs rapidly inflate to a pressure of 25 mm Hg, which is sustained for three seconds, followed by rapid deflation.
Participants will be asked to wear the device for two hours daily.
The device will inflate 180 times/hour.
|
Active Comparator: sham control + "no exercise" control
Participants will be asked to wear a sham intermittent pneumatic compression device for up to three hours daily.
The sham device inflates at the same frequency, but to a much lower systolic pressure, compared to the therapeutic pneumatic compression device.
Participants will be asked to participate in an educational/informational intervention, designed as an attention control group.
|
Participants attend health-education lectures and receive telephone calls at the same frequency as the exercise group.
On-site lectures are delivered by faculty and staff at the medical center.
Telephone calls review health-related handouts from the NIA website that are mailed in advance of the telephone call.
Content does not include exercise information.
The sham control device is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves.
The cuffs rapidly inflate to a pressure of 25 mm Hg, which is sustained for three seconds, followed by rapid deflation.
Participants will be asked to wear the device for two hours daily.
The device will inflate 180 times/hour.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Six-minute walk distance (intermittent pneumatic compression therapy + exercise v. exercise only)
Time Frame: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression combined with exercise improves the 6-minute walk at 6-month follow-up compared to exercise alone.
|
Baseline to 6-month follow-up
|
Six-minute walk distance (intermittent pneumatic compression therapy alone (without exercise) vs. sham alone (without exercise)
Time Frame: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone (without exercise) improves the 6-minute walk at 6-month follow-up, compared to the sham control alone (without exercise).
|
Baseline to 6-month follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Six-minute walk distance (intermittent pneumatic compression therapy + exercise v. exercise only)
Time Frame: Baseline to 12-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves the six-minute walk at 12-month follow-up, 6 months after the intermittent pneumatic compression therapy intervention is completed, compared to exercise alone.
|
Baseline to 12-month follow-up
|
Six-minute walk distance (IPC only v. sham only)
Time Frame: Baseline to 12-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves the six-minute walk distance at 12-month follow-up, 6 months after the intermittent pneumatic compression therapy intervention is completed, compared to the sham control.
|
Baseline to 12-month follow-up
|
Calf muscle perfusion (intermittent pneumatic compression therapy + exercise v. exercise only)
Time Frame: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves calf muscle perfusion at 6-month follow-up, compared to exercise alone.
|
Baseline to 6-month follow-up
|
Brachial artery FMD (intermittent pneumatic compression therapy + exercise v. exercise only)
Time Frame: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves brachial artery FMD at 6-month follow-up, compared to exercise alone.
|
Baseline to 6-month follow-up
|
Physical Activity measured by Actigraph activity monitor (intermittent pneumatic compression therapy + exercise v. exercise only)
Time Frame: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves physical activity measured by Actigraph activity monitor at 6-month follow-up, compared to exercise alone.
|
Baseline to 6-month follow-up
|
Calf muscle perfusion (intermittent pneumatic compression therapy + exercise v. exercise only)
Time Frame: Baseline to 12-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves calf muscle perfusion at 12-month follow-up, compared to exercise alone.
|
Baseline to 12-month follow-up
|
Brachial artery FMD (intermittent pneumatic compression therapy + exercise v. exercise only)
Time Frame: Baseline to 12-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves brachial artery FMD at 12-month follow-up, compared to exercise alone.
|
Baseline to 12-month follow-up
|
Physical Activity measured by Actigraph activity monitor (intermittent pneumatic compression therapy + exercise v. exercise only)
Time Frame: Baseline to 12-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves physical activity measured by Actigraph activity monitor at 12-month follow-up, compared to exercise alone.
|
Baseline to 12-month follow-up
|
Calf muscle perfusion (intermittent pneumatic compression therapy only v. sham only)
Time Frame: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves calf muscle perfusion at 6-month follow-up, compared to the sham control.
|
Baseline to 6-month follow-up
|
Brachial artery FMD (intermittent pneumatic compression therapy only v. sham only)
Time Frame: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves brachial artery FMD at 6-month follow-up, compared to the sham control.
|
Baseline to 6-month follow-up
|
Physical Activity measured by Actigraph activity monitor (intermittent pneumatic compression therapy only v. sham only)
Time Frame: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves physical activity measured by Actigraph activity monitor at 6-month follow-up, compared to the sham control.
|
Baseline to 6-month follow-up
|
Calf muscle perfusion (intermittent pneumatic compression therapy only v. sham only)
Time Frame: Baseline to 12-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves calf muscle perfusion at 12-month follow-up, compared to the sham control.
|
Baseline to 12-month follow-up
|
Brachial artery FMD (intermittent pneumatic compression therapy only v. sham only)
Time Frame: Baseline to 12-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves brachial artery FMD at 12-month follow-up, compared to the sham control.
|
Baseline to 12-month follow-up
|
Physical Activity measured by Actigraph activity monitor (intermittent pneumatic compression therapy only v. sham only)
Time Frame: Baseline to 12-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves physical activity measured by Actigraph activity monitor at 12-month follow-up, compared to the sham control.
|
Baseline to 12-month follow-up
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mitochondrial biogenesis (intermittent pneumatic compression therapy + exercise v. exercise only)
Time Frame: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves mitochondrial biogenesis (PGC-1α) at 6-month follow- up, compared to exercise alone.
|
Baseline to 6-month follow-up
|
Mitochondrial activity (intermittent pneumatic compression therapy + exercise v. exercise only)
Time Frame: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves mitochondrial activity (Cytochrome C oxidase) at 6-month follow- up, compared to exercise alone.
|
Baseline to 6-month follow-up
|
Vascular endothelial growth factor abundance (intermittent pneumatic compression therapy + exercise v. exercise only)
Time Frame: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves vascular endothelial growth factor abundance at 6-month follow- up, compared to exercise alone.
|
Baseline to 6-month follow-up
|
Anti-oxidant enzyme activity (intermittent pneumatic compression therapy + exercise v. exercise only)
Time Frame: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves anti-oxidant enzyme activity (MnSOD) at 6-month follow- up, compared to exercise alone.
|
Baseline to 6-month follow-up
|
Immunohistochemistry-measured mitochondrial activity (intermittent pneumatic compression therapy + exercise v. exercise only)
Time Frame: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves immunohistochemistry-measured mitochondrial activity (COX and SDH) at 6-month follow- up, compared to exercise alone.
|
Baseline to 6-month follow-up
|
Autophagy (intermittent pneumatic compression therapy + exercise v. exercise only)
Time Frame: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves autophagy (LC3, LAMP2, PARKIN) at 6-month follow- up, compared to exercise alone.
|
Baseline to 6-month follow-up
|
Capillary density (intermittent pneumatic compression therapy + exercise v. exercise only)
Time Frame: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves capillary density (CD31) at 6-month follow- up, compared to exercise alone.
|
Baseline to 6-month follow-up
|
Satellite cell content (intermittent pneumatic compression therapy + exercise v. exercise only)
Time Frame: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy combined with exercise improves satellite cell content (Pax7) at 6-month follow- up, compared to exercise alone.
|
Baseline to 6-month follow-up
|
Mitochondrial biogenesis (intermittent pneumatic compression therapy only v. sham only)
Time Frame: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves mitochondrial biogenesis (PGC-1α) at 6-month follow- up, compared to the sham control.
|
Baseline to 6-month follow-up
|
Mitochondrial activity (intermittent pneumatic compression therapy only v. sham only)
Time Frame: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves mitochondrial activity (Cytochrome C oxidase) at 6-month follow- up, compared to the sham control.
|
Baseline to 6-month follow-up
|
Vascular endothelial growth factor abundance (intermittent pneumatic compression therapy only v. sham only)
Time Frame: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves vascular endothelial growth factor abundance at 6-month follow- up, compared to the sham control.
|
Baseline to 6-month follow-up
|
Anti-oxidant enzyme activity (intermittent pneumatic compression therapy only v. sham only)
Time Frame: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves anti-oxidant enzyme activity (MnSOD) at 6-month follow- up, compared to the sham control.
|
Baseline to 6-month follow-up
|
Immunohistochemistry-measured mitochondrial activity (intermittent pneumatic compression therapy only v. sham only)
Time Frame: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves immunohistochemistry-measured mitochondrial activity (COX and SDH) at 6-month follow- up, compared to the sham control.
|
Baseline to 6-month follow-up
|
Autophagy (intermittent pneumatic compression therapy only v. sham only)
Time Frame: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves autophagy (LC3, LAMP2, PARKIN) at 6-month follow- up, compared to the sham control.
|
Baseline to 6-month follow-up
|
Capillary density (intermittent pneumatic compression therapy only v. sham only)
Time Frame: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves capillary density (CD31) at 6-month follow- up, compared to the sham control.
|
Baseline to 6-month follow-up
|
Satellite cell content (intermittent pneumatic compression therapy only v. sham only)
Time Frame: Baseline to 6-month follow-up
|
Among PAD participants, the investigators will determine whether intermittent pneumatic compression therapy alone improves satellite cell content (Pax7) at 6-month follow- up, compared to the sham control
|
Baseline to 6-month follow-up
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mary McDermott, MD, Northwestern Universtiy
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STU00208245
- 1R01AG057693-01A1 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Artery Disease
-
Janssen Scientific Affairs, LLCHCA Research Institute, LLCRecruitingCoronary Artery Disease (CAD) | Peripheral Artery Disease (PAD)United States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedStructural Heart Disease | Obstructive Coronary Artery Disease | Obstructive Peripheral Artery DiseaseUnited States
-
Fangge DengRecruitingPeripheral Artery Disease (PAD)China
-
Fundacion para la Formacion e Investigacion Sanitarias...Not yet recruiting
-
Rontis Hellas SAPharmassist LtdActive, not recruitingPeripheral Artery Disease (PAD)Greece
-
Michael Lichtenberg, MDCompletedPeripheral Artery Disease (PAD)Germany
-
Helsinki University Central HospitalCompletedPeripheral Artery Occlusive Disease | Peripheral Artery Stenosis | Peripheral Artery RestenosisFinland
-
Boston Scientific CorporationCompletedAtherosclerosis | Peripheral Artery Disease | Plaque, Atherosclerotic | Artery Diseases, Peripheral | Occlusive Arterial DiseaseUnited States, Belgium, Canada, Japan, Austria, New Zealand
-
Seung-Whan Lee, M.D., Ph.D.Active, not recruitingCatheterization, Peripheral | Popliteal Artery | Angioplasty, Balloon | Femoral ArteryKorea, Republic of
-
Dartmouth-Hitchcock Medical CenterSociety for Vascular SurgeryCompletedPeripheral Artery Disease (PAD)United States
Clinical Trials on intermittent pneumatic compression
-
Karolinska University HospitalEnrolling by invitationHealing Wound | Venous Stasis | Deep Venous ThrombosisSweden
-
Venous Health Systems, Inc.CompletedVenous ThrombosisUnited States
-
Walter Reed National Military Medical CenterWithdrawnEkbom Syndrome | Restless Legs Syndrome, | Restless Legs,United States
-
Feng TianActive, not recruitingApplication of IPC During Surgery to Prevent Venous Thrombosis in Gastrointestinal Surgery Patients.Stomach Neoplasms | Gastrointestinal Neoplasms | Intestinal NeoplasmsChina
-
Cwm Taf University Health Board (NHS)University of South WalesCompletedLymphoedema of LegUnited Kingdom
-
Western States Endurance Run Research FoundationCompletedMusculoskeletal PainUnited States
-
Centre Hospitalier Universitaire de NīmesWithdrawnMajor Abdominal SurgeryFrance
-
Marmara UniversityCompletedOsteoarthritis, Knee
-
National University Hospital, SingaporeCompletedDeep Vein Thrombosis | Ankle Joint ContractureSingapore
-
University of MaiaRecruitingEffects of Intermittent Pneumatic Compression Following Exercise-induced Muscle Damaged (IPC4sports)Sports Physical TherapyPortugal